News
Rifaximin-alpha use decreases healthcare utilisation in patients with cirrhosis and hepatic encephalopathy, with fewer ...
VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company”) announced today that its world-leading NAMkind™ platform for liver toxicology prediction, provided as a commercial service to pharma companies, was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback